Marker Therapeutics (MRKR) Capital Expenditures (2018 - 2023)
Marker Therapeutics (MRKR) posted quarterly Capital Expenditures of $141979.0 for Q1 2023, down 93.9% year-over-year from $2.3 million in Q1 2022, and up 675.02% quarter-over-quarter from -$24691.0 in Q4 2022.
Marker Therapeutics (MRKR) Capital Expenditures (2018 - 2023) Analysis & Trends
Marker Therapeutics (MRKR) has reported Capital Expenditures for 6 consecutive years, with $141979.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Capital Expenditures fell 93.9% year-over-year to $141979.0; the TTM figure through Mar 2023 stood at -$2.1 million (down 149.87% YoY), while the FY2022 annual figure was $57607.0, down 97.33% from the prior year.
- Capital Expenditures improved to $141979.0 in Q1 2023 per MRKR's latest filing, from -$24691.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $2.5 million in Q2 2020 and bottomed at -$2.3 million in Q2 2022.
- Historically, Capital Expenditures has averaged $236041.8 across 5 years, with a median of $66170.0 in 2022.
- Annual changes were most pronounced in 2020 — Capital Expenditures surged 1233.58% — and 2022, when it tumbled 3741.79%.
- Marker Therapeutics' Capital Expenditures stood at -$223126.0 in 2019, then plunged by 220.28% to -$714619.0 in 2020, then surged by 392.51% to $2.1 million in 2021, then tumbled by 101.18% to -$24691.0 in 2022, then soared by 675.02% to $141979.0 in 2023.
- Business Quant data shows MRKR's Capital Expenditures at $141979.0 in Q1 2023, -$24691.0 in Q4 2022, and $66170.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.65 Bn | 130.80 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.93 Bn | 77.94 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.84 Bn | 59.66 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.38 Bn | 52.25 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.94 Bn | 36.84 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.54 Bn | 28.23 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 27.72 Bn | 9.33 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 251.02 Mn |
| 10 | Marker Therapeutics | 26.85 Mn | 14.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 141,979.00 |
| Mar 31, 2023 | 141,979.00 |
| Dec 31, 2022 | -24,691.00 |
| Dec 31, 2022 | -24,691.00 |
| Sep 30, 2022 | 66,170.00 |
| Sep 30, 2022 | 66,170.00 |
| Jun 30, 2022 | -2.31 Mn |
| Jun 30, 2022 | -2.31 Mn |
| Mar 31, 2022 | 2.33 Mn |
| Mar 31, 2022 | 2.33 Mn |
| Dec 31, 2021 | 2.09 Mn |
| Dec 31, 2021 | 2.09 Mn |
| Sep 30, 2021 | -89,579.00 |
| Sep 30, 2021 | -89,579.00 |
| Jun 30, 2021 | -60,190.00 |
| Jun 30, 2021 | -60,190.00 |
| Mar 31, 2021 | 220,168.00 |
| Mar 31, 2021 | 220,168.00 |
| Dec 31, 2020 | -714,619.00 |
| Dec 31, 2020 | -714,619.00 |